• Pulmonary hypertension

Orenitram Generic Name & Formulations

General Description

Treprostinil 0.125mg, 0.25mg, 1mg, 2.5mg, 5mg; ext-rel osmotic tabs.

Pharmacological Class

Prostacyclin analogue.

How Supplied

Ext-rel tabs—10, 100

Generic Availability


Orenitram Indications


Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and improve exercise capacity.

Orenitram Dosage and Administration


Take with food. Swallow whole. Individualize. Initially 0.25mg twice daily (~12hrs apart) or 0.125mg three times daily (~8hrs apart). Titrate by 0.125 three times daily or 0.25mg or 0.5mg twice daily every 3–4 days; if not tolerated, consider slower titration. If intolerable adverse effects occur, decrease in 0.125mg or 0.25mg increments. Mild hepatic impairment (Child Pugh Class A) or concomitant strong CYP2C8 inhibitors: initially 0.125mg twice daily; titrate by increments of 0.125mg twice daily every 3–4 days. Moderate hepatic impairment (Child Pugh Class B): avoid. Treatment interruption/discontinuation or transitioning from SC/IV treprostinil: see full labeling.


Not established.

Orenitram Contraindications


Severe hepatic impairment (Child Pugh Class C).

Orenitram Boxed Warnings

Not Applicable

Orenitram Warnings/Precautions


Avoid abrupt withdrawal or sudden large dose reduction (see full labeling). Diverticulosis or blind-end pouches. Hepatic impairment. Elderly. Pregnancy. Nursing mothers.

Orenitram Pharmacokinetics

See Literature

Orenitram Interactions


Potentiated by CYP2C8 inhibitors (eg, gemfibrozil); see Adults.

Orenitram Adverse Reactions

Adverse Reactions

Headache, diarrhea, nausea, vomiting, flushing, pain in extremity, jaw pain, hypokalemia, abdominal discomfort.

Orenitram Clinical Trials

See Literature

Orenitram Note

Not Applicable

Orenitram Patient Counseling

See Literature